- Home
- ASM vs CMPX Comparison
ASM vs CMPX Comparison
Compare ASM & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | CMPX |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 926.7M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASM | CMPX |
|---|---|---|
| Price | $6.88 | $5.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $8.18 | ★ $14.43 |
| AVG Volume (30 Days) | ★ 4.2M | 1.8M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.91 | N/A |
| Revenue Next Year | $62.02 | $830.89 |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.37 | $1.33 |
| 52 Week High | $11.99 | $6.88 |
Technical Indicators
Market Signals| Indicator | ASM | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 32.61 |
| Support Level | $3.70 | $4.78 |
| Resistance Level | $9.70 | $5.86 |
| Average True Range (ATR) | 0.56 | 0.31 |
| MACD | -0.25 | -0.07 |
| Stochastic Oscillator | 0.69 | 8.00 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.